Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC) by unknown
Rodriguez et al. Translational Respiratory Medicine 2014, 2:10
http://www.transrespmed.com/content/2/1/10RESEARCH Open AccessExpression of transcript factors SALL4 and OCT4
in a subset of non-small cell lung carcinomas
(NSCLC)
Erika Rodriguez, Li Chen, Ming-Hui Ao, Susan Geddes, Ed Gabrielson, Frederic Askin, Hui Zhang and Qing Kay Li*Abstract
Background: SALL4 and OCT4 are transcription factors and play essential roles in stem cell development and
oncogenesis. However, the expression of these transcription factors has not been well studied in lung cancers. In this
study, we evaluated the expression of SALL4 and OCT4 in non-small cell lung carcinomas (NSCLC) by immunochemistry.
NSCLC tissue microarrays (TMAs) were constructed with a total of 77 primary lung adenocarcinomas (ADCs) and
90 primary lung squamous cell carcinomas (SqCCs). A mouse monoclonal anti-human SALL4 (1:400 dilution) and
a polyclonal anti-human OCT4 (1:200 dilution) antibodies were used. Nuclear staining of SALL4 and OCT4 was
scored semi-quantitatively using a three tiered scale. The expressions of SALL4 and OCT4 were correlated with
the tumor differentiation, pathological stage, and patients’ clinical information.
Results: In primary ADCs, the stronger expression of SALL4 and OCT4 was 7.8% and 9.1%, respectively. The
stronger expression of SALL4 was inversely correlated with tumor differentiations. In primary SqCCs, the stronger
expressions of SALL4 and OCT4 were 16.7% and 0%, respectively. The expression of SALL4 is correlated with the
expression of OCT4, but inversely correlated with the tumor stage in SqCCs.
Conclusions: We found that both SALL4 and OCT4 were differentially expressed in a subset of primary ADC and
SqCC. Our finding suggest that different stem cell markers may be expressed and/or play differential role in
different subtypes of NSCLC. The potential role of SALL4 and OCT4 needs to be further investigated in NSCLC.
Keywords: Transcription factor SALL4 and OCT4; Immunohistochemistry (IHC); Non-small cell lung cancer
(NSCLC); Metastatic NSCLC; Lung cancer biopsy and tissue microarray (TMA)Background
Lung cancer is one of the most common cancers world-
wide and in the United States [1]. It is the most common
cause of cancer-related death in both sexes [1]. Morpho-
logically, lung cancer can be divided in two major histo-
logical groups, non small cell (NSCLC) and small cell
carcinoma (SCLC). NSCLC is the most common type
and represents approximately 80% of all lung cancers
[2,3]. In NSCLCs, 70% of patients present with advanced
or metastatic disease at the diagnosis [1-3]. Recent mo-
lecular studies of NSCLC find that mutations of the EGFR
gene are present in 10-20% of lung adenocarcinomas
(ADC) and are associated with successful treatment with* Correspondence: qli23@jhmi.edu
Department of Pathology, The Johns Hopkins Medical Institutes, 4940 Eastern
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in any medium, provided the original work is pEGFR inhibitors [4,5], whereas KRAS mutations are
present in 20-30% of ADC and associated with non-
response to EGFR inhibitors [4-6]. Furthermore, the iden-
tification of EML4-ALK gene translocation in 3% of ADC
leads to targeted therapy with the ALK inhibitor crizotinib
[7]. NSCLC is, however, a heterogeneous group of neo-
plasms, with different morphologic subtypes, epigenetic
and molecular abnormalities, making targeted therapy and
treatment a challenge [4,6,8-10]. Therefore, the separ-
ation of diverse lung cancer phenotypes and gentotypes,
and the identification of novel markers have become
critically important for making therapeutic decisions
[4,6-11].
In recent years, the stem cell theory has become an
important paradigm in cancer development and progres-
sion. This theory proposes that tumor cells are organized
in a hierarchical manner, where cancer stem cells (CSC)is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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to embryonic stem cells [12-15]. CSCs have the ability to
self renew and give rise to a pool of undifferentiated
CSC, as well as more differentiated progeny cancer cells,
that form the bulk of the tumor mass [12-15]. CSCs
have been identified in hematologic malignancies as well
as in solid tumors such as melanoma, breast, brain,
prostate, pancreas and lung carcinomas [12-15]. In the
signaling network of CSC, several molecules such as Sal-
like protein 4 (SALL4), octamer-binding transcription
factor 4 (OCT4), Nanog and Klf4, have been identified
as important factors in maintaining the stem cell’s self-
renewal and dividing ability [16-18]. Based on the find-
ing that SALL4 regulates the activation and expression
of OCT4, Klf4 and other proteins [16-18], SALL4 has
been identified as one of the master transcription factors
in the molecular network which maintains the pluripo-
tency of stem cells [17,18]. Recently, a few studies have
provided the evidence that SALL4 also plays an import-
ant role in oncogenesis [19-23]. For example, the expres-
sion of SALL4 has been found in a subset of leukemia/
lymphomas [19], malignant rhabdoid tumors [20], germ
cell tumors [21], liver, and stomach carcinomas [22].
The expression of SALL4 has also been correlated with
different stages of colorectal [23] and breast cancers [24].
In lung cancer, the expression of CSC markers OCT4
and Nanog has been reported [25], however, the expres-
sion of SALL4 in NSCLC is still not well known. In this
study, we investigated the expression of SALL4 and
OCT4 using NSCLC tumor tissue microarrays (TMAs)
and immunohistochemistry; and correlated their expres-
sions with histological features of tumors and clinical
information of patients. The purpose of our study is to
examine the potential involvement of these CSC markers
in NSCLC.
Methods
Lung cancer tissue microarray (TMA) construction
The lung carcinoma tissue microarray (0.6 mm in diam-
eter, 3–4 cores per case) was constructed using surgical
resected specimens retrieved from the department of
pathology archives at The Johns Hopkins Hospitals over
a period of ten years (from 1999 to 2009). Tumor tissues
were fixed in 10% buffered formalin and embedded in
paraffin. A hematoxylin and eosin (H&E) stained section
of the paraffin-embedded tumor sample was reviewed by
the pathologist (QKL) to select the tumor area for TMA
construction. The World Health Organization criteria
were used to determine histological subtypes of lung
NSCLC [2,3]; and AJCC (American Joint Committee on
Cancer) 7th edition [26] was used to determine the
pathological stage of the tumor at the time of diagnosis.
A total of 77 cases of primary lung ADCs and 90 cases
of primary lung SqCCs were included.All tumor cases were annotated with available clinical
information in a manner that protected patient identity.
The use of human tumor tissue was approved by the
Johns Hopkins Institutional Review Board.
Immunohistochemistry (IHC)
IHC was performed on TMAs using the Dako autostai-
ner from the clinical immunohistochemistry laboratory
at the Johns Hopkins Hospitals. Sections of TMAs were
cut at 4 microns thickness and deparaffinized prior to
incubation with primary antibodies. Heat antigen re-
trieval at 70°C for 40 minutes was also used to enhance
signal detection. Primary antibodies were diluted accord-
ing to standard protocols and manufacturer suggestions.
A mouse monoclonal antibody against human SALL4
(clone 6e3, 1:400 dilution, SIGMA, St Louis, MO), and a
mouse polyclonal antibody against human OCT4 (clone
C-2, 1:200 dilution, ABCAM, Cambridge, MA) were
used. IHC of nuclei was scored based on the intensity
and percentage of stains using a semi-quantitatively
three tiered scale: 0 = negative, 1 = focally and weakly
positive (<20%), and 2 = positive (>20%). The IHC stains
on TMAs were scored by ER, MHA and QKL. If there
was a disagreement, the consensus was reached by dis-
cussion of the case among reviewers. Appropriate posi-
tive and negative controls were included in the IHC
assay.
Statistical analysis
Characteristics of clinical information and pathological
variables among different subsets of tumors were corre-
lated with the expression of SALL4 and OCT4. The Stu-
dent’s t-test and Fisher’s exact test were used. All tests




In primary lung ADC cases, the patients’ median age
was 63 years (range from 45 to 86 years). The male:
female ratio was: 1:0.97. Among tumors, 40 cases were
pT1, 31 cases were pT2, and 6 cases were pT3/4 tumors.
The mean tumor size was 3.07 cm, ranging from 0.5 to
9.0 cm. The subtypes of ADCs were as follows: mixed
(44 cases), acinar (19 cases), mucinous (6 cases), true
papillary (4 cases), solid (3 cases), and non-mucinous
ADC with lepidic pattern (formerly bronchioloalveolar
adenocarcinoma, 1 case). In SqCC cases, the patients’
median age was 64 years (range from 40 to 86 years).
The male: female ratio was: 1:0.60. Among tumors,
25 cases were pT1, 28 cases were pT2, 26 cases were
pT3 and 11 cases were pT4 tumors. The mean tumor
size was 4.32 cm, ranging from 0.20 to 13.5 cm. Clinical
information was summarized in Table 1. We did not




carcinomas (n = 90)
P values
Gender (cases (%))
0.1314Male 39 (50.6%) 56 (62.2%)
Female 38 (49.4%) 34 (37.8%)
Age (years)
0.9631Average ± SD 62.97 ± 13.62 63.06 ± 11.49
Range 45-86 40-86
Tumor size (cm)
0.0003Average ± SD 3.07 ± 1.81 4.32 ± 2.73




pT1 40 (51.9%) 25 (27.8%)
pT2 31 (40.3%) 28 (31.1%)
pT3 4 (5.2%) 26 (28.9%)
pT4 2 (2.6%) 11 (12.2%)
SD: standard deviation. N/A: not applicable.
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gender between ADC and SqCC (p > 0.05, p = 0.9631
and p = 0.1314, respectively). The average tumor size of
SqCC is 4.32 cm, and it was significantly larger than the
average size of 3.07 cm in ADCs (p < 0.001, p = 0.0003).
Expression of SALL4 and OCT4 in normal tissue and
primary NSCLC
In our study, 112 normal tissues were included as con-
trols in TMAs. The expression of SALL4 and OCT4
were summarized in Table 2. Immunoreactivities of
SALL4 and OCT4 were negative in 75% (n = 84) andTable 2 Expressions of SALL4 and OCT4 in normal tissues
Tissue SALL4 expression
Negative (0) Score (1+)
Lymphoid tissue (n = 22) 19 3
Kidney (n = 11) 10 1
Smooth muscle (n = 4) 4 0
Brain (n = 5) 5 0
Fibroconnective tissue (n = 9) 9 0
Lung (n = 10) 9 1
Skin (n = 2) 1 1
Placenta (n = 6) 3 3
Pancreas acini (n = 5) 5 0
Salivary glands (n = 2) 2 0
Prostate (n = 7) 3 3
GI tract (n = 29) 14 7
Total (n = 112, 100%) 84 (75%) 19 (17%)79% (n = 88) cases, respectively. In SALL4, 9 cases (8%)
were 2+ scores, and most of these cases were found in
gastrointestinal (GI) epithelium. The weak and focal
immunoreactivity were found in GI, germinal center
cells of lymphoid tissue, kidney tubular cells, basal cells
of bronchial epithelium, prostate, skin, and placental
trophoblasts. Similarly, in OCT4, the most immunoreac-
tivity was found in the skin, GI epithelium, prostate,
lung and few other tissues.
The expression of SALL4 and OCT4 in primary lung
ADC and SqCC was summarized in Table 3 and Figure 1.
In 77 ADCs, the expression of SALL4 was negative in
66.2%, weakly positive in 26.0% and positive in 7.8%
cases. In 90 SqCCs, SALL4 was negative in 62.2%,
weakly positive in 21.1% and positive in 16.7% of cases.
The stronger expression of SALL4 was found more fre-
quent in SqCC than that in ADC. The expression of
OCT4 in these two groups was as follows: in ADC, OCT4
was negative in 62.3%, weakly positive in 27.3% and posi-
tive in 9.1% cases, whereas, the expression of OCT4 in
SqCCs was negative in 74.4%, weakly positive in 25.6% and
positive in 0% cases. The stronger expression of OCT4 was
found more frequent in ADC than that in SqCC.
We further examined SALL4 and OCT4 expression in
different subtypes of ADC (Tables 4 and 5). The stronger
expression of SALL4 was found in several subtypes of
ADC, whereas, OCT4 expression was found predomin-
ately in the mixed subtype of ADCs.
Both SALL 4 and OCT4 play important roles in em-
bryonic development and oncogenesis. Human SALL4
gene is the homolog of the Drosophila gene sal-like 4
[27,28] and located on the long (q) arm of chromosome
20 at position 13.2 [28]. The functional role of SALL4
has been suggested as the essential transcript factor inOCT4 expression
Score (2+) Negative (0) Score (1+) Score (2+)
0 22 0 0
0 9 2 0
0 4 0 0
0 5 0 0
0 9 0 0
0 7 3 0
0 0 0 2
0 5 1 0
0 5 0 0
0 2 0 0
1 4 3 0
8 16 13 0
9 (8%) 88 (79%) 22 (20%) 2 (1%)
Table 3 IHC stains of SALL4 and OCT4 in primary lung
ADC and SqCC
NSCLC SALL4 expression OCT4 expression
Negative Score Score Negative Score Score N/A
































*One case did not have tumor tissue on the TMA.
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liferation [16-18]. In addition to play an important role
in human embryonic development, mutation of SALL4
gene has been related to several congenital and develop-
mental abnormalities, such as DRRS (Duane-Radial Ray
Syndrome) and acro-renal-ocular syndrome [29]. In ani-
mal studies, the constitutive expression of SALL4 in
transgenic mice has been linked to the development of
acute myeloid leukemia and lymphocytic leukemia [30].
In human, the overexpression of SALL4 has been re-
ported in hematologic malignancies such as acute mye-
locytic and lymphocytic leukemia [19]; and in solid
tumors such as malignant rhabdoid tumor [20], germ
cell tumor [21], liver and stomach [22], colorectal [23]
and breast cancers [24]. Furthermore, SALL4 has also
been detected in Wilms tumor, but not in nephrogenic
rests, this observation suggests that SALL4 could be
used as a protein marker in the distinction of these two
entities [31]. Similarly, OCT4 is also an important regu-
lator of stem cell differentiation and plays an essential
role in embryogenesis [25,32]. OCT4 expression has
been reported in different types of cancers and involved





Figure 1 SALL4 and OCT4 expressions in NSCLC. A-C, immunostains of S
score 1 = focally and weakly positive (<20%), and score 2 = positive (>20%).In lung cancers, the expression of OCT4 and Nanog
has been reported [25,32], however, the expression of
SALL4 in NSCLC has not been well studied. Our study
by using lung cancer TMA and immunohistochemistry
demonstrated that both SALL4 and OCT4 are expressed
in a subset of NSCLC. In primary ADCs, the stronger
expression of SALL4 and OCT4 was 7.8% and 9.1%. In
primary SqCCs, the stronger expressions of SALL4 and
OCT4 were 16.7% and 0%, respectively. The stronger ex-
pression of SALL4 is more frequently detected in SqCCs
than in ADCs. In contrast, the stronger expression of
OCT4 is more frequently detected in lung ADCs.
Expressions of SALL4 and OCT4 among differently
differentiated tumors
We also examined and correlated expressions of SALL4
and OCT4 among differently differentiated tumors. Data
were summarized in Figures 2 and 3. In 77 ADCs, 12
cases were well differentiated, 52 cases were moderately
differentiated and 13 cases were poorly differentiated. The
expressions of SALL4 and OCT4 showed different patterns
(Figure 2). The stronger SALL4 expression was found more
frequently in poorly differentiated ADCs, and it was in-
versely correlated with the tumor differentiation. In
contrast, the stronger OCT4 expression was found more
frequently in well differentiated ADCs. The inversed rela-
tionship of SALL4 and OCT4 expression and tumor dif-
ferentiation was found. However, the statistical analysis
did not found significant differences between groups.
In 90 SqCCs, 4 cases were well differentiated, 64 cases
were moderately differentiated and 22 cases were poorly
differentiated. The expressions of SALL4 and OCT4
showed different patterns (Figure 3). The stronger SALL4
expression was found in both poorly and moderately dif-
ferentiated SqCC. But, this pattern was not found inC
F
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Figure 2 SALL4 and OCT4 expressions in differently differentiated
primary lung adenocarcinomas (ADCs). In 77 ADCs, 12 cases were
well differentiated, 52 cases were moderately differentiated and 13
cases were poorly differentiated. The expressions of SALL4 and OCT4
showed different patterns.







Mixed (n = 44) 30 (68.2%) 13 (29.6%) 1 (2.3%)
Acinar (n = 19) 13 (68.4%) 3 (15.8%) 3 (15.8%)
Mucinous (n = 6) 4 (66.7%) 1 (16.7%) 1 (16.7%)
True papillary (n = 4) 3 (75.0%) 1 (25.0%) 0 (0.0%)
Solid (n = 3) 0 (0.00%) 2 (66.7%) 1 (33.3%)
Lepidic (n = 1) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Total (n = 77) 51 (66.2%) 20 (26.0%) 6 (7.8%)
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quent in well differentiated SqCCs. However, the statistical
analysis did not found significant differences between
groups.
Recent studies of the molecular mechanism of SALL4
in stem cells have shown that SALL4 activates transcrip-
tional factor OCT4, interacts with Nanog, and forms a
protein-protein complex in SALL4/ Oct4/Nanog signal-
ing pathway [18]. More recently, the detection of SALL4
in germ cell tumors [21] suggests the clinical utility of
this protein as a biomarker for diagnosing primary and
metastatic germ cell tumors in a variety of anatomic sites
such as brain, testes, ovary and mediastinum. In our study,
we observed that SALL4 was more frequently expressed
in poorly differentiated tumors, whereas, OCT4 was more
frequently expressed in well differentiated tumors. Our
data suggested that SALL4 and OCT4 may play a differen-
tial role in the process of tumor differentiation.
Correlation of SALL4 and OCT4 expression between
tumor stage and patients’ survival time
The expressions of SALL4 and OCT4 among different





Negative Score Score N/A
(0) (1+) (2+)
Mixed (n = 44) 23 (52.3%) 14 (31.8%) 6 (13.6%) 1 (2.3%)*
Acinar (n = 19) 15 (77.0%) 4 (21.1%) 0 (0.0%)
Mucinous (n = 6) 5 (83.3%) 1 (16. 7%) 0 (0.0%)
True papillary (n = 4) 2 (50.0%) 2 (50.0%) 0 (0.0%)
Solid (n = 3) 3 (100.0%) 0 (0.0%) 0 (0.0%)
Lepidic (n = 1) 0 (0.00) 0 (0.0%) 1 (100.0%)
Total (n = 77) 48 (62.3%) 21 (27. 3%) 7 (9.1%) 1 (1.3%)
N/A: not applicable.
*One case did not have tumor tissue on the TMA.Figures 4 and 5. In 77 ADCs, 40 cases were pT1, 31
cases were pT2, and 6 cases were pT3/4 tumors. The
stronger expressions of SALL4 and OCT4 were found
more frequently in pT1 ADCs (Figure 4), and showed
a borderline difference in OCT4 expression (p < 0.05,
p = 0.0429). In 90 SqCCs, 25 cases were pT1, 28 cases
were pT2, and 37 cases were pT3/4 tumors. The ex-
pressions of SALL4 and OCT4 showed different pat-
terns (Figure 5). The stronger SALL4 expression was
found in all different stages of SqCCs. But, this pattern
was not found in OCT4 expressions. The stronger
OCT4 expression was more frequently detected in
pT3/4 SqCCs. However, the statistical analysis did not
found significant differences between groups.
We also correlated expression of SALL4 and OCT4
with patients’ survival time (Table 6). Although patients
with tumors that expressed SALL4 and OCT4 seemed
to have short survival time, we did not find significant
differences of survival time among different groups of
patients.
The potential relationship of SALL4 and OCT4 in primary
NSCLC
In our study, the expression of SALL4 and OCT4 is dif-
ferent in different subtypes of NSCLC. In primary






























Figure 4 SALL4 and OCT4 expressions in different stages of
primary lung adenocarcinomas (ADCs). In 77 ADCs, 40 cases were
pT1, 31 cases were pT2, and 6 cases were pT3/4 tumors. The stronger








































Figure 5 SALL4 and OCT4 expressions in different stages of
primary lung squamous cell carcinomas (SqCCs). In 90 SqCCs, 25
cases were pT1, 28 cases were pT2, and 37 cases were pT3/4 tumors.
The expressions of SALL4 and OCT4 showed different patterns. The
stronger SALL4 expression was found in all different stages of SqCCs.








































Figure 3 SALL4 and OCT4 expressions in differently
differentiated primary lung squamous cell carcinomas (SqCCs).
In 90 SqCCs, 4 cases were well differentiated, 64 cases were
moderately differentiated and 22 cases were poorly differentiated.
The expressions of SALL4 and OCT4 showed different patterns.
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stronger expressions of SALL4 and OCT4 were 16.7%
and 0%, respectively. The stronger expression of SALL4
is more frequently detected in SqCCs than in ADCs,
whereas, the stronger expression of OCT4 is more fre-
quent detected in lung ADCs. The Fisher’s exact test
showed that the stronger expression of SALL4 (with
score 2+) in SqCC and the stronger expression of
OCT4 (with score 2+) in ADC were significantlyTable 6 Correlation of SALL4 and OCT4 expression with
patients’ survival time
Markers Adenocarcinoma Squamous cell
carcinomas
(n = 77) (n = 90)
Average survival
months (cases)
P value Average survival
months (cases)
P value
SALL4 Negative 35.63 ± 3.18
(n = 51)
0.9866 36.98 ± 4.71
(n = 56)
0.3684




OCT4 Negative 38.73 ± 4.24
(n = 47)
0.1666 35.75 ± 4.54
(n = 67)
0.4815
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sion of SALL4 was inversely correlated with tumor dif-
ferentiations in both ADC and SqCC. However, the
expression of SALL4 was correlated with tumor stage
and the expression of OCT4 only in SqCC. We also
correlated the expression of SALL4 and OCT4 with the
EGFR and KRAS mutations in ADCs. Among 77 ADCs,
we only found 3 tumors had EGFR mutations and 5 tu-
mors with KRAS mutations. Thus, we are unable to
draw a conclusion based on this small number. Taken
together, our findings suggest that different stem cell
markers may be expressed and/or play different roles in
different stages of NSCLCs.
An early study of SALL4 signaling pathway has found
that SALL4 and OCT4 form a positive feedback loop
[18]. In the network, SALL4 not only activates OCT4
expression, but is also positively regulated by OCT4 ex-
pression [18]. In addition to this positive regulatory
mechanism, Yang et al. have also found that SALL4 is
regulated by the auto-regulation mechanism of self-
repression, which acts as a “gate keeper” or a “break”
mechanism for the SALL4/OCT4 positive feedback loop
[18]. Although both OCT4 and SALL4 have been con-
sidered to play important roles in oncogenesis, the dif-
ferential expression of SALL4 and OCT4 in lung
primary ADCs and SqCCs suggests that NSCLCs may
be regulated differently in the SALL4 signaling pathway.
Finally, similar to the study of breast cancer [24], we do
not find that the expression of SALL4 is correlated with
tumor stage or patients’ survival time. The potential role
of SALL4 and OCT4 in NSCLC needs to be further
studied.
In a recent mechanism study of Kobayashi et al., they
analyzed SALL4 mRNA levels in lung cancer tissue and
found that SALL4 mRNA was highly expressed in lung
cancers [33]. They also compared SALL4 mRNA levels
in tumor tissue with non-neoplastic tissue from the
same patient and found that 93% of tumor cases had a
greater than two-fold increase in SALL4 mRNA. In the
study, they also found that SALL4 siRNA treatment in
lung cancer cells dramatically inhibited cell growth via
cell cycle arrest at the G1 and early S phases, indicating
that SALL4 might be involved in the G1 phase transition
of the cell cycle. These studies suggest that SALL4 ex-
pression may play a potential role in the regulation of
lung cancer development.
Conclusions
We examined the expression of SALL4 and OCT4 in
NSCLC tumor tissue using TMA and IHC stains. We
found that both SALL4 and OCT4 were expressed in a
subset of primary NSCLC, including both ADCs and
SqCCs. The stronger expression of SALL4 is more fre-
quently detected in SqCCs than in ADCs. In contrast,the stronger expression of OCT4 is more frequent de-
tected in lung ADCs. In primary ADCs, the stronger ex-
pression of SALL4 and OCT4 was 7.8% and 9.1%. The
stronger expression of SALL4 was inversely correlated
with tumor differentiation. In primary SqCCs, the stronger
expressions of SALL4 and OCT4 were 16.7% and 0%, re-
spectively. The expression of SALL4 correlated with the
expression of OCT4, but inversely correlated with the
tumor stage in SqCCs. Taken together, our findings sug-
gest that different stem cell markers may be expressed
and/or play different roles in different subtypes of
NSCLCs. In addition, our data also suggests that NSCLC
should be added to the differential diagnosis of SALL4/
OCT4 positive neoplasms, particularly in patients with
mediastinal tumors. Future studies are necessary to clarify
the potential role of SALL4 and OCT4 in NSCLCs.
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